GST Reforms Transform India’s Pharmaceutical & Healthcare Sector

India’s recent Goods and Services Tax (GST) reforms are reshaping the pharmaceutical and healthcare industry, enhancing patient affordability, streamlining compliance, and boosting India’s global standing as the ‘Pharmacy of the World’ and an innovation hub.

GST Cuts Enhance Patient Affordability

The GST Council has reduced rates on all medicines (except exempted drugs) from 12% to 5%, directly lowering out-of-pocket expenses for patients. Medicines remain a non-discretionary household expense, and the tax reduction significantly eases the financial burden on families.

Additionally, the Council exempted 36 essential medicines, including life-saving drugs for cancer, rare diseases, and critical treatments, from GST. These measures particularly benefit patients requiring long-term or specialised therapies.

Over the past year, coordinated fiscal reforms—including a reduction in Basic Customs Duty (BCD) on cancer formulations and the September 2025 GST rationalisation- have cut prices of key medicines, yielding up to 14.2% savings for consumers.

The reforms reflect strong collaboration between industry, regulators such as the National Pharmaceutical Pricing Authority (NPPA), and trade bodies.

Regular dialogue ensured a balance between industry sustainability and patient affordability, promoting transparent, predictable, and patient-focused policies.

Lower GST rates will reduce medicine prices for consumers, boosting goodwill for the industry. Companies must now ensure the benefits are passed on transparently across the supply chain.

However, the transition presents challenges. Businesses must adjust invoicing, pricing, and distribution systems while navigating complexities such as zero-GST input tax credit calculations. Coordinated efforts are essential to realign MRPs and ensure smooth implementation at retail levels.

These reforms go beyond taxation, laying the foundation for a more efficient, inclusive, and transparent healthcare system. By easing financial strain on patients, the government encourages higher consumption of quality healthcare services, driving investment and innovation in the sector.

Industry stakeholders, including OPPI and member companies, have pledged to deliver GST benefits efficiently and transparently to patients, ensuring affordability and access remain central to India’s healthcare vision.

Also Read: India’s Petroleum Product Exports Rise To One-Year High In September